Get the Stockscreener App
19.59
0.31%
0.06
Pre-market:
19.50
-0.09
-0.46%
Kodiak Sciences Inc stock is traded at $19.59, with a volume of 731.65K.
It is up +0.31% in the last 24 hours and up +10.68% over the past month.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
See More
Previous Close:
$19.53
Open:
$20.42
24h Volume:
731.65K
Relative Volume:
0.83
Market Cap:
$1.03B
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-5.2101
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
+3.82%
1M Performance:
+10.68%
6M Performance:
+382.51%
1Y Performance:
+238.34%
1-Day Range:
$19.26
$20.86
1-Week Range:
$18.14
$22.14
52-Week Range:
$1.92
$22.14
Kodiak Sciences Inc Stock (KOD) Company Profile
Name
Kodiak Sciences Inc
Sector
Industry
Phone
650-281-0850
Address
1250 PAGE MILL RD, PALO ALTO, CA
Compare KOD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KOD
Kodiak Sciences Inc
|
19.59 | 1.04B | 0 | -197.68M | -158.88M | -3.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.32 | 106.82B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.00 | 73.86B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
445.79 | 60.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.50 | 56.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
199.64 | 43.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-24-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-25-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Sep-22-25 | Initiated | Jefferies | Buy |
| Aug-14-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-09-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| Dec-11-23 | Resumed | Goldman | Sell |
| Nov-17-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Jul-27-23 | Downgrade | UBS | Buy → Neutral |
| Jul-25-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jul-25-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jul-24-23 | Downgrade | Jefferies | Buy → Hold |
| Nov-15-22 | Initiated | CapitalOne | Overweight |
| Aug-02-22 | Downgrade | Citigroup | Neutral → Sell |
| Feb-24-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-11-22 | Initiated | Goldman | Buy |
| Feb-02-22 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-12-21 | Initiated | Evercore ISI | Outperform |
| Mar-01-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-17-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-11-20 | Initiated | Citigroup | Neutral |
| Nov-30-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-13-20 | Downgrade | Goldman | Buy → Neutral |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-03-20 | Initiated | Goldman | Buy |
| Feb-18-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-06-20 | Initiated | SunTrust | Buy |
| Jan-08-20 | Initiated | ROTH Capital | Buy |
| Jan-03-20 | Initiated | Jefferies | Buy |
| Dec-24-19 | Initiated | JP Morgan | Overweight |
| Oct-15-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-20-19 | Initiated | Chardan Capital Markets | Buy |
| Oct-29-18 | Initiated | Barclays | Overweight |
| Oct-29-18 | Initiated | BofA/Merrill | Buy |
| Oct-29-18 | Initiated | Morgan Stanley | Overweight |
View All
Kodiak Sciences Inc Stock (KOD) Latest News
Is Kodiak Sciences Inc. (K27) stock prepared for digital transitionMarket Sentiment Summary & Long-Term Safe Investment Ideas - newser.com
How Kodiak Sciences Inc. (K27) stock reacts to monetary easingJuly 2025 Opening Moves & Intraday High Probability Alerts - newser.com
Does Kodiak Sciences Inc. (K27) stock trade below intrinsic valueMarket Rally & Low Drawdown Investment Ideas - newser.com
What downside risks could hit Kodiak Sciences Inc. (K27) stockTrade Performance Summary & Growth Focused Entry Point Reports - newser.com
Is Kodiak Sciences Inc. (K27) stock testing key supportFed Meeting & Real-Time Chart Pattern Alerts - newser.com
Best data tools to analyze Kodiak Sciences Inc. stockEarnings Recap Summary & Entry Point Confirmation Signals - newser.com
How analysts revise price targets for Kodiak Sciences Inc. (K27) stockTrade Exit Report & Technical Entry and Exit Alerts - newser.com
How Kodiak Sciences Inc. (K27) stock valuation compares with sectorPortfolio Return Summary & Weekly Stock Breakout Alerts - newser.com
Will Kodiak Sciences Inc. (K27) stock outperform foreign stocksCPI Data & Weekly Top Performers Watchlists - newser.com
Kodiak Sciences stock hits 52-week high at 21.18 USD By Investing.com - Investing.com Nigeria
Kodiak Sciences : Jefferies Global Healthcare Conference London November 2025 - MarketScreener
Kodiak Sciences stock hits 52-week high at 21.18 USD - Investing.com India
KOD Maintains Neutral Rating by Chardan Capital | KOD Stock News - GuruFocus
Kodiak Sciences stock price target raised to $26 from $24 at H.C. Wainwright - Investing.com India
KOD: HC Wainwright Maintains Buy Rating, Raises Price Target to $26 | KOD Stock News - GuruFocus
HC Wainwright & Co. Maintains Kodiak Sciences (KOD) Buy Recommendation - Nasdaq
How to manage a losing position in Kodiak Sciences Inc.Market Risk Summary & Safe Swing Trade Setup Alerts - newser.com
What indicators show strength in Kodiak Sciences Inc.Volume Spike & Expert Curated Trade Setups - newser.com
Does Kodiak Sciences Inc. show high probability of reboundWeekly Risk Report & Weekly Top Gainers Trade List - newser.com
Published on: 2025-11-16 06:53:16 - newser.com
Can technical indicators confirm Kodiak Sciences Inc.’s reversalIPO Watch & Consistent Growth Stock Picks - newser.com
Is Kodiak Sciences Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Proven Capital Preservation Methods - newser.com
Will Kodiak Sciences Inc. stock deliver consistent dividendsTrade Volume Summary & High Accuracy Trade Signal Alerts - newser.com
What candlestick patterns are forming on Kodiak Sciences Inc.Weekly Trade Recap & Weekly Hot Stock Watchlists - newser.com
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus - sharewise.com
Decoding Kodiak Sciences Inc (KOD): A Strategic SWOT Insight - GuruFocus
Should I hold or sell Kodiak Sciences Inc. stock in 2025Price Action & Growth Focused Investment Plans - newser.com
How Kodiak Sciences Inc. stock reacts to Fed rate cutsQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Resistance Check: Why Kodiak Sciences Inc. (K27) stock is a strong analyst pickMarket Risk Analysis & Reliable Price Breakout Alerts - Fundação Cultural do Pará
Kodiak Sciences Inc Stock (KOD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):